Breakthrough PTSD treatment achieves 68% remission rate in clinical trial
A newly FDA-cleared PTSD treatment uses personalized brain mapping and magnetic stimulation to target abnormal brain activity, with a clinical trial reporting a 52% reduction in symptoms and 68% remission. Researchers believe the technology could transform PTSD care and pave the way for more precise treatments for other mental health conditions.
Original source
This story is summarized for discovery. Read the full report at the original publisher.
Read original article ↗